Interview: Xu Hang – CEO, Mindray, China
In the last decade the medical device sector has undergone a lot of change; China has become a net importer to a net exporter of these devices. What is your…
Address: Mindray Building, Keji 12th Road South, High-tech Industrial Park, Nanshan, Shenzhen 518057, P. R. China.,China
Tel: +86 (755) 26582888
Web: http://www.mindray.com/main/index.jsp
Mindray was founded in 1991 in Shenzhen, China, with a mission to deliver high-quality, competitively priced medical devices to make healthcare more accessible and affordable around the world. Over the last 18 years, Mindray has become a leading developer, manufacturer and marketer of medical devices worldwide. According to Frost & Sullivan, in 2006 Mindray attained a leading market share in China both by units sold and revenue for the sale of patient monitoring devices. Mindray also holds a leading market share in China in the three-part differentiation hematology analyzer, biochemistry analyzer and black and white ultrasound imaging system segments.
Our success has been deeply rooted in our commitment to invest approximately 10% of our revenues into R&D every year. With more than 1,530 engineers on staff, Mindray has built a world-class platform that capitalizes on low-cost China based R&D operations and a culture that is driven by ingenuity, and both individual and team performance. Mindray currently offers more than 40 products across three business segments including patient monitoring devices and life support products, in-vitro diagnostic instruments and medical imaging systems. Mindray expects to continue to introduce six to eight new products each year to broaden market reach. Mindray is confident that our growing comprehensive portfolio of high-quality, affordable products will allow the company to continue gaining market share both domestically and internationally.
In China, Mindray has distributed products to over 40,000 hospitals, clinics, and healthcare facilities. Outside China, Mindray has sold devices in over 190 countries. Mindray began exporting our products for the first time in 2000; and in the second half of 2007, revenues generated from international markets exceeded domestic revenues for the first time in Mindray’s operating history.
By June 2009, Mindray had a total of approximately 5,600 employees worldwide, and Mindray is expanding its distribution, sales and service network to bring products closer to end users. Mindray currently has 29 branch companies in major cities of China, as well as 12 overseas subsidiaries in Amsterdam, Frankfurt, Istanbul, London, Mexico City, Milan, Moscow, Mumbai, Sao Paulo, Seattle, Toronto and Vancouver.
Mindray’s American Depositary Shares (ADSs) are listed on the New York Stock Exchange (NYSE) under the symbol MR.
patient monitoring, diagnostics and ultrasound imaging systems
In the last decade the medical device sector has undergone a lot of change; China has become a net importer to a net exporter of these devices. What is your…
Dr Yangzhou Wang, chief operations officer of Crown Bioscience (CrownBio), shares the new era of development for the company following its acquisition by a Japanese industrial conglomerate in December 2017;…
In late 2018 China adopted a novel procurement scheme with the aim of dramatically cutting the amount being paid for generic drugs. The policy’s effect on pricing stands to hit…
Adam Dunnett, secretary general of the European Union Chamber of Commerce in China (European Chamber) outlines the organization’s three key roles of advocacy, providing business intelligence and strengthening the European…
Andras Gizur, president China & APAC for Gedeon Richter, shares his insights on the current market environment in China following the spate of recent healthcare reforms, the exciting innovations Gedeon…
Davide Dalle Fusine, general manager for Chiesi China, shares the key milestones for the company in the past five years, their leadership position in neonatology and strength respiratory franchise in…
Pierre Faury, co-President of the French Healthcare Alliance in China as well as vice-President of Sanofi China in charge of Commercial Excellence, shares the mandate of the French Healthcare Alliance…
Tony Au, general manager of AbbVie China, shares the key milestones for the affiliate in the past six years, the strong foundation he has built for AbbVie in China, the…
China is set to become the second largest market for Mundipharma’s OxyContin behind the US. It comes as no surprise that sales of opioids such as OxyContin have plummeted…
Dr Dan Zhang, CEO of Fountain Medical Development (FMD), details the transformation China’s recent membership at the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human…
Dr Wang Yinxiang, chairman; and Dr Hu Shaojing, President (R&D); of Jacobio Pharmaceutical; share the exciting story behind Jacobio’s establishment in 2015, their ambition to become a global biopharma player…
Alan Chen, general manager for Ipsen China, shares the exciting journey of Ipsen in China in the past few years as the third-largest affiliate for the group globally, upcoming innovative…
Dr Michael Yu, founder, Chairman and CEO of Innovent Biologics, one of China’s most successful and innovative biopharma start-up, shares his long-term vision to build a company that can last…
See our Cookie Privacy Policy Here